Following the November meeting of GMMMG, the formulary has been updated to reflect decisions made by the Clinical Reference Group (CRG) and Medicines and Guidelines Subgroup (MGSG). Changes include:
- Addition of NICE technology appraisals and MHRA drug safety updates to formulary
- Ustekinumab dose escalation in inflammatory bowel disease commissioning statement updated to include latest evidence
For full details of the changes, please see the Formulary Change Log.